J Hypertens:高血压和多种心血管危险因素会增加视网膜静脉阻塞的风险

2019-05-06 xing.T 网络

由此可见,心血管危险因素比RVO存在的其他危险因素更重要。增加任何一个额外的危险因素,RVO的风险增加约40%,增加任何一个额外的心血管危险因素风险增加70%。

虽然几种视网膜静脉阻塞(RVO)的危险因素是已知的,但在许多情况下,引发RVO的原因尚不清楚。近日,高血压领域权威杂志Journal of Hypertension上发表了一篇研究文章,研究人员旨在评估RVO患者中多种危险因素的相关性。

Gutenberg RVO研究是一项观察性病例对照研究,评估RVO参与者以及相同数量的匹配对照者的血栓形成、血管、眼科和药物相关危险因素。条件logistic回归分析来估计由于几个风险因素导致的RVO风险。

92例RVO患者中,46例(50%)患有中央性RVO,31例(33.7%)患有分支RVO,15例(16.3例)患有半RVO。全身性高血压与RVO相关[任何RVO:比值比(OR):1.81; 95%置信区间(CI):1.14-2.88; 分支RVO:OR:2.56; 95%CI:1.08-6.10]。最常见的危险因素组合是高血压伴血脂异常(92例中的33例,占35.9%)和高同型半胱氨酸血症以及高水平的因子VIII(92例中10例,占10.9%)。风险总和得分增加一个额外危险因素对应血管危险因素的OR为1.74(95%CI:1.31-2.32),血栓形成危险因素的OR为1.38(95%CI:1.04-1.82),RVO的危险因素总数的OR为1.43(95%CI:1.20-1.70)。 

由此可见,心血管危险因素比RVO存在的其他危险因素更重要。增加任何一个额外的危险因素,RVO的风险增加约40%,增加任何一个额外的心血管危险因素风险增加70%。 

原始出处:

Ponto, Katharina A.et al.Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions results from the Gutenberg Retinal Vein Occlusion Study.Journal of Hypertension. 2019.https://journals.lww.com/jhypertension/Abstract/publishahead/Hypertension_and_multiple_cardiovascular_risk.97203.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2020-01-02 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2020-03-09 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-08-26 fusion
  6. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-05-08 zutt
  7. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1696882, encodeId=d7c316968823d, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jan 02 11:33:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727978, encodeId=da071e27978ad, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Mar 09 09:33:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948939, encodeId=607b1948939fb, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Sep 04 17:33:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039050, encodeId=9cb2203905072, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Oct 16 15:33:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697896, encodeId=9615169e89679, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Aug 26 15:33:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270188, encodeId=6b9512e018895, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331498, encodeId=2b4113314984b, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581622, encodeId=ea25158162288, content=<a href='/topic/show?id=0f8e90830d9' target=_blank style='color:#2F92EE;'>#视网膜静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90830, encryptionId=0f8e90830d9, topicName=视网膜静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629784, encodeId=1dde1629e8442, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Wed May 08 10:33:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]

相关资讯

这4种特殊类型高血压的治疗 不仅仅是降压这么简单

高血压是最常见的慢性病,是以动脉血压持续升高为特征的心血管综合征,其定义为在未使用降压药的情况下,非同日3次测量,收缩压≥140mmHg和/或舒张压≥90mmHg。近年来,随着研究的不断深入,发现部分患者的高血压类型比较特殊,是高血压中比较棘手的,只有针对它们的形成原因对症治疗,才能取得明显的效果。阻塞性睡眠呼吸暂停相关性高血压阻塞性睡眠呼吸暂停综合征(OSAS)导致血压升高的机制不明确。OSAS

Circulation:依帕列净可有效用于糖尿病合并高血压的黑人患者

Empagliflozin(依帕列净)是一种用于2型糖尿病(T2DM)的钠-葡萄糖共转运体2抑制剂,可降低T2DM患者的血压(BP)和心血管疾病的死亡率。但其是否可用于黑种人尚未有相关研究。研究人员开展一24周研究,评估依帕列净用于T2DM和高血压黑人患者的疗效和安全性。共招募了150位患者,52.7%为男性,平均年龄56.8(9.3)岁;平均T2DM患病时间9.3(7.1)年。起始时的重要参数:

BMJ Open:高血压与听力损伤相关性研究

因为听力的恢复非常的困难,因此听力损伤(HI)的预防非常重要。流行病学研究已经调查了HI的风险因子,然而,高血压与HI之间的相关性仍旧不清楚。最近,有研究人员鉴定了高血压与HI之间的相关性。在24823名在同一个公司工作的工作者中,研究人员在年度健康检查中招募了13475名经历听力测试的参与者。另外,还包括了体重测量、血液检测和喝酒/抽烟状态等数据(平均年龄:49.4岁;男性:86.4%)。研究发

Eur Heart J:高血压等慢性病既伤“心”又伤“脑”

高血压、糖尿病等慢性病是导致人们患上心脏疾病的几个主要风险因素。一项最新研究发现,这些慢性病不但伤“心”,而且伤“脑”,会使人脑出现结构性变化导致痴呆症的风险升高。

研究:高血压等慢性病既伤“心”又伤“脑”

高血压、糖尿病等慢性病是导致人们患上心脏疾病的几个主要风险因素。一项最新研究发现,这些慢性病不但伤“心”,而且伤“脑”,会使人脑出现结构性变化导致痴呆症的风险升高。研究人员近期在《欧洲心脏病学杂志》上介绍,他们分析了9772名年龄在44岁至79岁志愿者的相关数据。这些人至少接受过一次磁共振成像大脑扫描,并提供了个人基本健康情况及就医记录等。数据分析发现,心血管疾病的风险因素中,除了高胆固醇之外,其

高血压治疗药物依从性的测量方法学

治疗依从性是目前公认的抗高血压治疗有效性的关键,然而在高血压管理中常常被忽视,原因是依从性评估的方法用于临床中没有统一标准并极其复杂,临床存在局限性,现有证据表明:在无症状的慢性疾病中普遍依从性低,包括高血压病、糖尿病、血脂异常,药物依从性差会破坏药物治疗的预期,增加心脑血管疾病、肾脏疾病发生发展的风险。本文总结40年的临床研究结果,就依从性测量方法,包括间接方法和直接方法来衡量药物的依从性,